PPAR Medicines and Human Disease: The ABCs of It All

ATP-dependent binding cassette (ABC) transporters are a family of transmembrane proteins that pump a variety of hydrophobic compounds across cellular and subcellular barriers and are implicated in human diseases such as cancer and atherosclerosis. Inhibition of ABC transporter activity showed promise in early preclinical studies; however, the outcomes in clinical trials with these agents have not been as encouraging. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that regulate genes involved in fat and glucose metabolism, and inflammation. Activation of PPAR signaling is also reported to regulate ABC gene expression. This suggests the potential of PPAR medicines as a novel means of controlling ABC transporter activity at the transcriptional level. This paper summarizes the advances made in understanding how PPAR medicines affect ABC transporters, and the potential implications for impacting on human diseases, in particular with respect to cancer and atherosclerosis.

[1]  Merlin C. Thomas,et al.  Direct antiatherosclerotic effects of PPAR agonists , 2009, Current opinion in lipidology.

[2]  A. Tall,et al.  Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins , 2008, Journal of internal medicine.

[3]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[4]  W. Haefeli,et al.  Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. , 2004, Biochemical pharmacology.

[5]  W. Haefeli,et al.  Interaction of Thiazolidinediones (Glitazones) with the ATP-Binding Cassette Transporters P-Glycoprotein and Breast Cancer Resistance Protein , 2009, Pharmacology.

[6]  Karim Benkirane,et al.  Vascular and Cardiac Effects in Hypertension , 2022 .

[7]  B. Spiegelman,et al.  International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.

[8]  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001 .

[9]  D. Kelsell,et al.  Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. , 2005, American journal of human genetics.

[10]  A. Tall,et al.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.

[11]  P. Elias,et al.  Regulation of ABCA1 expression in human keratinocytes and murine epidermis Published, JLR Papers in Press, July 6, 2006. , 2006, Journal of Lipid Research.

[12]  B. Staels,et al.  Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. , 2003, The Biochemical journal.

[13]  R. Bendayan,et al.  Regulation of Breast Cancer Resistant Protein by Peroxisome Proliferator-Activated Receptor α in Human Brain Microvessel Endothelial Cells , 2012, Molecular Pharmacology.

[14]  M. Haber,et al.  Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer , 2007, IUBMB life.

[15]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[16]  A. Vaughan,et al.  The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. , 1999, The Journal of clinical investigation.

[17]  Chava Kimchi-Sarfaty,et al.  P-glycoprotein: from genomics to mechanism , 2003, Oncogene.

[18]  J. Peters,et al.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention , 2012, Nature Reviews Cancer.

[19]  A. Tall,et al.  ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Doyle,et al.  Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. , 2001, Biochemical and biophysical research communications.

[21]  J. Plutzky Inflammation in Atherosclerosis and Diabetes Mellitus , 2004, Reviews in Endocrine and Metabolic Disorders.

[22]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Curtis D. Klaassen,et al.  INDUCTION OF THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN FAMILY OF TRANSPORTERS BY CHEMICAL ACTIVATORS OF RECEPTOR-MEDIATED PATHWAYS IN MOUSE LIVER , 2005, Drug Metabolism and Disposition.

[24]  R. Paoletti,et al.  Advances in Lipid Research , 1988 .

[25]  R. Johnstone,et al.  The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[27]  M. Vázquez-Carrera,et al.  Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. , 2004, Biochemical pharmacology.

[28]  T. Willson,et al.  Triglyceride:High-Density Lipoprotein Cholesterol Effects in Healthy Subjects Administered a Peroxisome Proliferator Activated Receptor &dgr; Agonist , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[29]  J. Auwerx,et al.  Cross-Talk between Fatty Acid and Cholesterol Metabolism Mediated by Liver X Receptor-α , 2000 .

[30]  K. Yoshizato,et al.  Bezafibrate induces multidrug‐resistance P‐Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[31]  Kazumitsu Ueda,et al.  Fenofibric Acid, an Active Form of Fenofibrate, Increases Apolipoprotein A-I–Mediated High-Density Lipoprotein Biogenesis by Enhancing Transcription of ATP-Binding Cassette Transporter A1 Gene in a Liver X Receptor–Dependent Manner , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[32]  S. Jameson,et al.  Expression of the transcription factor lung Krüppel-like factor is regulated by cytokines and correlates with survival of memory T cells in vitro and in vivo. , 1999, Journal of immunology.

[33]  D. Mogilenko,et al.  PPARγ activates ABCA1 gene transcription but reduces the level of ABCA1 protein in HepG2 cells. , 2010, Biochemical and biophysical research communications.

[34]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[35]  E. Barta,et al.  Peroxisome Proliferator-activated Receptor γ-regulated ABCG2 Expression Confers Cytoprotection to Human Dendritic Cells* , 2006, Journal of Biological Chemistry.

[36]  J. Berger,et al.  PPARs: therapeutic targets for metabolic disease. , 2005, Trends in pharmacological sciences.

[37]  Z. Varghese,et al.  J Am Soc Nephrol 14: 593–600, 2003 PPAR Agonists Protect Mesangial Cells from Interleukin 1�- Induced Intracellular Lipid Accumulation by Activating the , 2022 .

[38]  S. Salomone Pleiotropic Effects of Glitazones: A Double Edge Sword? , 2011, Front. Pharmacol..

[39]  J. Auwerx,et al.  Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients , 1997, Diabetes.

[40]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[41]  Jingqing Yang,et al.  The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. , 2005, Cancer research.

[42]  S. Kaye Reversal of drug resistance in ovarian cancer: where do we go from here? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[44]  T. Rajkumar,et al.  Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line , 2008, Anti-cancer drugs.

[45]  A. Adem,et al.  Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators , 2011, The open medicinal chemistry journal.

[46]  Michael Müller,et al.  Gene expression of transporters and phase I/II metabolic enzymes in murine small intestine during fasting , 2007, BMC Genomics.

[47]  W. Wahli,et al.  New insights into the role of PPARs. , 2011, Prostaglandins, leukotrienes, and essential fatty acids.

[48]  K. Motojima,et al.  PPARα Agonists Positively and Negatively Regulate the Expression of Several Nutrient/Drug Transporters in Mouse Small Intestine , 2007 .

[49]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[50]  M. Hamburg,et al.  Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. , 2010, The New England journal of medicine.

[51]  B. Barna,et al.  Restoration of PPARγ reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[52]  C. Atalay,et al.  Multidrug Resistance in Locally Advanced Breast Cancer , 2006, Tumor Biology.

[53]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[54]  C. Fielding,et al.  Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.

[55]  J. Tanabe,et al.  Effects of combined PPARγ and PPARα agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat , 2008 .

[56]  Y. Uehara,et al.  Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARγ/LXRα pathway: findings from in vitro and ex vivo studies. , 2011, Atherosclerosis.

[57]  M. Price,et al.  New strategies in managing and preventing atherosclerosis: focus on HDL. , 2002, Reviews in cardiovascular medicine.

[58]  T. Harkness,et al.  Troglitazone reverses the multiple drug resistance phenotype in cancer cells , 2009, Drug design, development and therapy.

[59]  D. Rees,et al.  ABC transporters: the power to change , 2009, Nature Reviews Molecular Cell Biology.

[60]  S. Yokoyama,et al.  On the mechanism for PPAR agonists to enhance ABCA1 gene expression. , 2009, Atherosclerosis.

[61]  M. Jaye,et al.  PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.

[62]  S. Jane,et al.  Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux , 2004, Cell Death and Differentiation.

[63]  P. Edwards,et al.  Regulation of ABCG1 expression in human keratinocytes and murine epidermis[S] , 2006, Journal of Lipid Research.

[64]  R. Ringseis,et al.  Conjugated Linoleic Acid Isomers Reduce Cholesterol Accumulation in Acetylated LDL-Induced Mouse RAW264.7 Macrophage-Derived Foam Cells , 2008, Lipids.

[65]  E. Araki,et al.  Telmisartan Exerts Antiatherosclerotic Effects by Activating Peroxisome Proliferator-Activated Receptor-&ggr; in Macrophages , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[66]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[67]  H. Kim,et al.  Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  A. Rigotti,et al.  Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. , 1996, The Biochemical journal.

[69]  R. Ringseis,et al.  13-hydroxy linoleic acid increases expression of the cholesterol transporters ABCA1, ABCG1 and SR-BI and stimulates apoA-I-dependent cholesterol efflux in RAW264.7 macrophages , 2011, Lipids in Health and Disease.

[70]  G. Gibbons,et al.  Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. , 2003, Journal of lipid research.

[71]  A. Tedgui,et al.  CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. , 2000, Circulation.

[72]  Jie Zhou 周 洁,et al.  Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARγ activation by troglitazone , 2010, Journal of Huazhong University of Science and Technology [Medical Sciences].

[73]  D. Arnett,et al.  Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. , 2010, Molecular genetics and metabolism.

[74]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[75]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.

[76]  V. Preedy,et al.  Randomized Controlled Trial , 2010 .

[77]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[78]  I. Holen,et al.  Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies , 2011, International journal of breast cancer.

[79]  Philippe Chavatte,et al.  Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. , 2012, Journal of medicinal chemistry.

[80]  H. Brewer,et al.  High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[81]  Yong-Xu Wang PPARs: diverse regulators in energy metabolism and metabolic diseases , 2010, Cell Research.

[82]  M. Akiyama Pathomechanisms of harlequin ichthyosis and ABCA transporters in human diseases. , 2006, Archives of dermatology.

[83]  W. Wahli,et al.  PPARs in diseases: control mechanisms of inflammation. , 2005, Current medicinal chemistry.

[84]  Y. Sugiyama,et al.  Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. , 2004, Journal of lipid research.

[85]  B. Staels,et al.  Peroxisome proliferator-activated receptor α (PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice , 2004 .

[86]  C. Glass,et al.  Conditional Disruption of the Peroxisome Proliferator-Activated Receptor γ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux , 2002, Molecular and Cellular Biology.

[87]  M. Vázquez-Carrera,et al.  Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. , 2006, Biochemical pharmacology.

[88]  H. Choi,et al.  The Effect of PPARα and PPARγ Ligands on Inflammation and ABCA1 Expression in Cultured Gallbladder Epithelial Cells , 2008, Digestive Diseases and Sciences.

[89]  J. R. McMillan,et al.  Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. , 2005, The Journal of clinical investigation.

[90]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[91]  B. Staels,et al.  Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. , 2003, Gastroenterology.

[92]  Y. Nishiwaki,et al.  Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[93]  Jeffrey S Moffit,et al.  Induction of Hepatic Transporters Multidrug Resistance-Associated Proteins (Mrp) 3 and 4 by Clofibrate Is Regulated by Peroxisome Proliferator-Activated Receptor α , 2006, Journal of Pharmacology and Experimental Therapeutics.

[94]  W. K. Roberts,et al.  Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. , 1997, Biochemistry.

[95]  P. Barter,et al.  Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[96]  R. Evans,et al.  A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .

[97]  P. Elias,et al.  Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders. , 2007, Advances in dermatology.

[98]  C. Klaassen,et al.  Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[99]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[100]  J. Peters,et al.  Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[101]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[102]  K. Brouwer,et al.  Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[103]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[104]  Liyan Yu,et al.  Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARγ-LXRα-ABCA1 pathway. , 2011, Biochemical and biophysical research communications.

[105]  C. Weber,et al.  Atherosclerosis: current pathogenesis and therapeutic options , 2011, Nature Medicine.

[106]  P. Elias,et al.  Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. , 2006, The Journal of investigative dermatology.

[107]  S. Cole,et al.  Mammalian multidrug-resistance proteins (MRPs). , 2011, Essays in biochemistry.

[108]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[109]  C. Glass,et al.  PPARs and molecular mechanisms of transrepression. , 2007, Biochimica et biophysica acta.

[110]  D. Curiel,et al.  A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. , 2008, Blood.

[111]  P. Libby,et al.  Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro , 1998 .

[112]  P. Elias,et al.  Ceramide Stimulates ABCA12 Expression via Peroxisome Proliferator-activated Receptor δ in Human Keratinocytes* , 2009, The Journal of Biological Chemistry.

[113]  J. Piette,et al.  Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 , 1999, Nature Genetics.

[114]  Elisabetta Poluzzi,et al.  Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting , 2011, Diabetes Care.

[115]  S. Yokoyama,et al.  Effects of Fibrate Drugs on Expression of ABCA1 and HDL Biogenesis in Hepatocytes , 2008, Journal of cardiovascular pharmacology.

[116]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[117]  P. Elias,et al.  PPAR and LXR activators regulate ABCA12 expression in human keratinocytes. , 2008, The Journal of investigative dermatology.

[118]  Robert A Hegele,et al.  Retinoid X receptor heterodimers in the metabolic syndrome. , 2005, The New England journal of medicine.

[119]  S. Cole,et al.  Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.

[120]  H. Uno,et al.  Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. , 2010, Blood.

[121]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[122]  B. Spiegelman PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[123]  B. Staels,et al.  Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* , 1998, The Journal of Biological Chemistry.

[124]  P. Elias,et al.  The biochemistry and function of stratum corneum lipids. , 1991, Advances in lipid research.

[125]  J. Fletcher,et al.  ABC transporters in cancer: more than just drug efflux pumps , 2010, Nature Reviews Cancer.

[126]  M. Lazar,et al.  Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.